Lu Xu
About Lu Xu
Vice President of Development Sciences at Bolt Biotherapeutics
Lu Xu joined Bolt Biotherapeutics in 2022 as the Vice President of Development Sciences. With this role, Lu Xu is responsible for overseeing the company’s scientific development initiatives and ensuring the effective progression of antibody-based therapeutics, particularly in the field of oncology. Lu Xu's role involves leading teams and guiding the development process from early research stages through to post-marketing commitments.
Lu Xu’s Experience in Antibody-Based Therapeutics
Lu Xu brings 20 years of experience in the development of antibody-based therapeutics, with a strong focus on oncology. Throughout a distinguished career, Lu Xu has managed and supported new drug development programs from early-stage research to post-marketing commitments, contributing significantly to 12 Investigational New Drugs (INDs) and two Biologics License Applications (BLAs). This extensive experience positions Lu Xu as a key player in advancing novel therapeutic strategies in the biotechnology sector.
Former Co-Founder and Head of Drug Development at PRAV Biosciences
Before joining Bolt Biotherapeutics, Lu Xu co-founded PRAV Biosciences and served as the head of drug development. In this role, Lu Xu was instrumental in shaping the company's drug development strategy and execution, leading efforts to bring innovative therapeutic solutions to clinical practice. This leadership experience has equipped Lu Xu with a deep understanding of the challenges and opportunities in the biotech industry.
Leadership Roles at 23andMe Therapeutics and OncoMed Pharmaceuticals
Lu Xu held significant positions at 23andMe Therapeutics, including head of preclinical development and clinical pharmacology. Here, Lu Xu was responsible for preclinical safety assessments, pharmacokinetics, biomarker discovery, and bioanalytics. At OncoMed Pharmaceuticals, Lu Xu served as the head of clinical pharmacology and preclinical pharmacokinetics, supporting the planning and execution of multiple oncology programs from pre-IND stages through Phase 2 clinical studies. These roles involved critical oversight and strategic planning essential for advancing therapeutic development efforts.
Educational Background of Lu Xu
Lu Xu holds a Ph.D. in biomedical engineering and an M.S. in regulatory science from the University of Southern California. Additionally, Lu Xu earned an M.S. in biochemistry from the University of California, Riverside. This strong educational foundation in both scientific and regulatory disciplines has provided Lu Xu with the skills necessary to navigate the complex landscape of drug development in the biotechnology industry.